ENHERTU Advances First-Line Endometrial Therapy in Phase 3 Trial
ENHERTU Phase 3 trial launches for first-line endometrial therapy targeting HER2-expressing tumors.
ENHERTU Phase 3 trial launches for first-line endometrial therapy targeting HER2-expressing tumors.